pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression

World Journal of Surgical Oncology

Volumn 13, Issue 1, 2015, Pages

  Wang, Min ^a   Lu, Xingjiao ^b   Dong, Xueguang ^a   Hao, Fengyun ^c,d   Liu, Zimin ^a,c   Ni, Guangzhen ^d   Chen, Dong ^c  

^a Affiliated Laiwu Hospital   (China)

^b People's Hospital of Zhangqiu   (China)

^c QINGDAO UNIVERSITY   (China)

^d WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

Bax; Bcl 2; ERK1 2; Gemcitabine; Pancreatic cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; BAX PROTEIN, HUMAN; DEOXYCYTIDINE; MAPK1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NICK END LABELING; PANCREAS CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84924136950     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-015-0451-7     Document Type: Article

References (24)

1. Squadroni M, Fazio N. Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 2010;14:386-3894.
2. Burris III HA, Moore MJ, Anderson J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
3. Rothenberg ML, Moore MJ, Cripps MC. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer. Ann Oncol. 1996;7:347-53.
4. van Riel JMGH, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol. 1999;10:S157-61.
5. Kroep JR, Pinedo CJ, van Groeningen CJ. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol. 1999;10:S234-8.
6. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-51.
7. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006;13:933-9.
8. Zheng C, Jiao X, Jiang Y, Sun S. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J Int Med Res. 2013;41:300-6.
9. Hengartner MO. The biochemistry of apoptosis. Nature. 2010;407:770-6.
10. Lutz RJ. Role of the BH3 (bcl-2 homology 3) domain in the regulation of apoptosis and bcl-2-related proteins. Biochem Soc Trans. 2000;28:51-6.
11. Reed JC. bcl-2 family proteins. Oncogene. 1998;17:3225-36.
12. Weinmann P, Bommert K, Mapara MY, Dörken B, Bargou RC. Overexpression of the death-promoting gene bax-alpha sensitizes human BL-41 Burkitt lymphoma cells for surface IgM-mediated apoptosis. Eur J Immunol. 2007;27:2466-8.
13. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, et al. bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med. 2007;11:349-61.
14. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004;109:182-8.
15. Pirocanac EC, Nassirpour R, Yang M, Wang J, Nardin SR, Gu J, et al. bax-induction gene therapy of pancreatic cancer. J Surg Res. 2002;106:346-51.
16. Seino S, Sunayama J, Matsuda KI, Sato A, Matsumoto Y, Nomiya T, et al. MEK-ERK-dependent multiple caspase activation by mitochondrial proapoptotic bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death. Cell Death Dis. 2002;1:e60.
17. Zhang W, Zhao L, Liu J, Du J, Wang Z, Ruan C, et al. Cisplatin induces platelet apoptosis through the ERK signaling pathway. Thromb Res. 2012;130:81-91.
18. Pan TL, Wang PW, Leu YL, Wu TH, Wu TS. Inhibitory effects of Scutellaria baicalensis extract on hepatic stellate cells through inducing G2/M cell cycle arrest and activating ERK-dependent apoptosis via bax and caspase pathway. J Ethnopharmacol. 2012;139:829-37.
19. Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-37.
20. Boucher MJ, Morisset J, Vachon PH, Reed JC, Lainé J, Rivard N. MEK/ERK signaling pathway regulates the expression of bcl-2, bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79:355-69.
21. Peyssonnaux C, Eyche'ne A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53-62.
22. Tang Y, Liu F, Zheng C, Sun S, Jiang Y. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer Res. 2012;31:73.
23. Sartorius UA, Krammer PH. Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 2002;97:584-92.
24. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456-9.